Researchers find breastfeeding can reduce women’s risk of metabolic syndrome

Researchers from Hallym University's College of Medicine in Seoul Korea found in a new study that women who breastfeed longer during their lifetimes may be able to lower their risk of metabolic syndrome and other disorders.

The study, published in the Journal of Women’s Health, examined more than 4,700 Korean women aged 19-50 years.

Results showed that women who breastfed for 12 months or longer had a lower risk of developing metabolic syndrome and elevated blood pressure, glucose and triglyceride levels.

"The advantageous effects of breastfeeding for newborns and babies are well established, and this study, which suggests that breastfeeding may protect the mother against metabolic syndrome, further adds to the evidence base supporting the benefits of breastfeeding for maternal health," said Susan G. Kornstein, MD, editor-in-chief of Journal of Women's Health and president of the Academy of Women's Health, in a statement.

Other authors include Se Run Choi, Yong Min Kim, Min Su Cho, So Hyum Kim and Young Suk Shim.  

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.